Baseline inflammatory markers, including C-reactive protein and interleukin-6, can provide an objective reference point for assessing systemic anti-inflammatory effects where that is a stated goal
Lillys Immunology, Oncology, and Neuroscience medicines collectively grew 160% year over year
Other studies suggest the drug could benefit people with sleep apnea, addiction, anxiety, Parkinsons, kidney disease and fatty liver disease.
: , ,
Afamelanotide was approved by the European Medicines Agency in 2014 under the brand name Scenesse for the prevention of phototoxicity in patients with erythropoietic protoporphyria
Weinberg Sibony, R., Segev, O., Dor, S